HPR Stock Overview
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Horizon Therapeutics Public Limited Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$110.20 |
| 52 Week High | US$110.80 |
| 52 Week Low | US$61.68 |
| Beta | 1.01 |
| 1 Month Change | 3.38% |
| 3 Month Change | 17.86% |
| 1 Year Change | 67.30% |
| 3 Year Change | 54.28% |
| 5 Year Change | 601.91% |
| Change since IPO | 1,783.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| HPR | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.2% | -4.9% | -1.5% |
| 1Y | 67.3% | -19.9% | 0.9% |
Return vs Industry: HPR exceeded the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: HPR exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| HPR volatility | |
|---|---|
| HPR Average Weekly Movement | 2.8% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HPR has not had significant price volatility in the past 3 months.
Volatility Over Time: HPR's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 2,190 | Tim Walbert | www.horizontherapeutics.com |
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use.
Horizon Therapeutics Public Limited Company Fundamentals Summary
| HPR fundamental statistics | |
|---|---|
| Market cap | €25.30b |
| Earnings (TTM) | €416.06m |
| Revenue (TTM) | €3.46b |
60.8x
P/E Ratio7.3x
P/S RatioIs HPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HPR income statement (TTM) | |
|---|---|
| Revenue | US$3.64b |
| Cost of Revenue | US$824.98m |
| Gross Profit | US$2.82b |
| Other Expenses | US$2.38b |
| Earnings | US$438.00m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.91 |
| Gross Margin | 77.36% |
| Net Profit Margin | 12.02% |
| Debt/Equity Ratio | 48.2% |
How did HPR perform over the long term?
See historical performance and comparison